AstraZeneca shares rise
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
Lord Storey says he fears Merseyside was "not a high priority" on the government's growth agenda.
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback